血管生成素-2预测危重症患者急性肾损伤及其与ARDS的关联
该队列研究在283例危重症患者中检测入ICU 24小时内血浆AGPT1和AGPT2,发现AGPT2及AGPT2/AGPT1比值与严重AKI相关,但该关联仅在ARDS患者中显著;在ARDS患者中加入AGPT2可显著提升严重AKI预测能力。
要点
- ARDS患者入ICU时AGPT2水平高于非ARDS患者。
- AGPT2与严重AKI的关联仅在ARDS患者中显著,非ARDS患者中不显著。
- ARDS患者中加入AGPT2可显著改善严重AKI预测(NRI 64.1%,IDI 0.057)。
核心结论
- AGPT2及AGPT2/AGPT1比值与严重AKI及需要RRT相关,但该关联仅见于ARDS患者或存在ARDS风险者,其他危重症患者中不显著。
- 在ARDS患者中,将AGPT2加入临床模型可显著提升严重AKI预测能力。
研究设计与样本
- 队列研究,纳入283例危重症患者(男性50.2%),其中109例(38.5%)患有ARDS。
- 入ICU后24小时内采集血浆检测AGPT1和AGPT2。
- 结局指标为严重AKI和需要透析(RRT)。
主要发现
- ARDS患者入ICU时AGPT2水平更高。
- 总体AGPT2及AGPT2/AGPT1水平与严重AKI相关,但非ARDS患者中该关联不显著,ARDS患者中仍强烈显著。
- 非ARDS患者中AGPT2预测严重AKI的AUC为0.64,ARDS组为0.81。
- ARDS组加入AGPT2的连续NRI为64.1%(P < 0.001),IDI为0.057(P = 0.003);非ARDS组NRI无显著差异。
关键数值与推荐
- ARDS组AGPT2预测严重AKI的AUC为0.81,非ARDS组为0.64。
- ARDS组加入AGPT2的连续NRI为64.1%(P < 0.001),IDI为0.057(P = 0.003)。
临床怎么用
- 在ARDS患者中可考虑检测入ICU 24小时内血浆AGPT2以辅助严重AKI风险分层。
- 非ARDS危重症患者中AGPT2对严重AKI的预测价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Angiopoietin-2 (AGPT2) has been proposed as a key mediator of organ dysfunction, mainly in acute respiratory distress syndrome (ARDS). It has also been associated with acute kidney injury (AKI). We aimed to investigate the role of AGPT2 in patients with and without ARDS. METHODS: In a cohort study with critically ill patients, AGPT1 and AGPT2 were assayed in plasma collected within the first 24 h after admission to intensive care unit (ICU). Severe AKI and the need for dialysis were outcome measures from comparative analysis with clinical characteristics useful for AKI risk stratification. RESULTS: Among 283 patients (50.2% males), 109 (38.5%) had ARDS. AGPT2 levels at admission were higher in patients with ARDS. Although overall AGPT2 and AGPT2/AGPT1 levels were associated with severe AKI, this association was not significant in patients without ARDS; however, it remained strongly significant in ARDS patients. In patients without ARDS, AGPT2 showed only a weak discriminatory capacity to predict severe AKI (area under the curve (AUC): 0.64 vs 0.81 in the ARDS group). The continuous net reclassification improvement (NRI) in the ARDS group resulting from AGPT2 inclusion was 64.1% (P < 0.001) and the integrated discrimination improvement (IDI) index was 0.057 (P = 0.003). There was no significant difference in NRI in the no-ARDS group. CONCLUSION: AGPT2 and AGPT2/AGPT1 ratio are associated with severe AKI and there was only a need of renal replacement therapy (RRT) in patients with or at risk of ARDS, not in other critically ill patients. Adding AGPT2 to a clinical model resulted in a significant improvement in the capacity to predict severe AKI specifically in ARDS patients.
引用
- Araújo CB, de Oliveira Neves FM, de Freitas DF, et al. Angiopoietin-2 as a predictor of acute kidney injury in critically ill patients and association with ARDS. Respirology. 2019. PMID: 30654408. doi:10.1111/resp.13464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。